In addition, engineered erythrocyte-derived extracellular vesicles (RBC EVs) immobilized with gp350 by electroporation showed enhanced tumor-specific targeting of CD21 B-cell malignancies while minimizing systemic toxicity. The gene discussed is CR2; the disease is neoplasm.